Document is current

Any future updates will be listed below

S292L mutation in Rv1258c efflux pump drives pyrazinamide efflux and a novel inhibitor designed for co-therapy to improve MDR-TB treatment outcomes

Crossref DOI link: https://doi.org/10.1007/s11274-025-04510-8

Published Online: 2025-08-07

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark